Cargando…
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
BACKGROUND: Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related disease because the incidence of most cancers increases with age, new drugs should also be evaluated in older patients to assess their...
Autores principales: | Baldini, C., Charton, E., Schultz, E., Auroy, L., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Le Gouill, S., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.J., Delord, J.P., Roca, C. Gomez, Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.C., Massard, C., Besle, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271476/ https://www.ncbi.nlm.nih.gov/pubmed/35533427 http://dx.doi.org/10.1016/j.esmoop.2022.100468 |
Ejemplares similares
-
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
por: Charton, E., et al.
Publicado: (2023) -
Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
por: Samaille, T., et al.
Publicado: (2021) -
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015) -
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
por: Even, C., et al.
Publicado: (2019) -
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis
por: Moreau Bachelard, Camille, et al.
Publicado: (2021)